166 related articles for article (PubMed ID: 33880639)
21. Methadone rotation versus other opioid rotation for refractory cancer induced bone pain: protocol of an exploratory randomised controlled open-label study.
Michael N; Sulistio M; Wojnar R; Gorelik A
BMC Palliat Care; 2023 Apr; 22(1):42. PubMed ID: 37059995
[TBL] [Abstract][Full Text] [Related]
22. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
[TBL] [Abstract][Full Text] [Related]
23. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
24. Methadone for cancer pain.
Nicholson AB
Cochrane Database Syst Rev; 2004; (2):CD003971. PubMed ID: 15106230
[TBL] [Abstract][Full Text] [Related]
25. Practicability, safety, and efficacy of a "German model" for opioid conversion to oral levo-methadone.
Ostgathe C; Voltz R; Van Aaaken A; Klein C; Sabatowski R; Nauck F; Gaertner J
Support Care Cancer; 2012 Sep; 20(9):2105-10. PubMed ID: 22130587
[TBL] [Abstract][Full Text] [Related]
26. Patient-controlled analgesia with oral methadone in cancer pain: preliminary report.
Mercadante S; Sapio M; Serretta R; Caligara M
Ann Oncol; 1996 Aug; 7(6):613-7. PubMed ID: 8879376
[TBL] [Abstract][Full Text] [Related]
27. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
28. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain.
Bruera E; Watanabe S; Fainsinger RL; Spachynski K; Suarez-Almazor M; Inturrisi C
Pain; 1995 Aug; 62(2):141-146. PubMed ID: 8545138
[TBL] [Abstract][Full Text] [Related]
29. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
30. Methadone for cancer pain.
Nicholson AB
Cochrane Database Syst Rev; 2007 Oct; (4):CD003971. PubMed ID: 17943808
[TBL] [Abstract][Full Text] [Related]
31. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
32. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
Chiou TJ; Chao TC; Chao TY; Huang JS; Chang YF; Wang CH
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1179. PubMed ID: 32721110
[TBL] [Abstract][Full Text] [Related]
33. Methadone in the treatment of pain and terminal delirum in advanced cancer patients.
Moryl N; Kogan M; Comfort C; Obbens E
Palliat Support Care; 2005 Dec; 3(4):311-7. PubMed ID: 17039986
[TBL] [Abstract][Full Text] [Related]
34. Methadone response in advanced cancer patients with pain followed at home.
Mercadante S; Casuccio A; Agnello A; Barresi L
J Pain Symptom Manage; 1999 Sep; 18(3):188-92. PubMed ID: 10517040
[TBL] [Abstract][Full Text] [Related]
35. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
36. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
Kleeberg UR; Davies A; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
Eur J Pain; 2015 Apr; 19(4):528-37. PubMed ID: 25181451
[TBL] [Abstract][Full Text] [Related]
37. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
38. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
39. Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain?
Cherny N
Palliat Med; 2011 Jul; 25(5):488-93. PubMed ID: 21708855
[TBL] [Abstract][Full Text] [Related]
40. Clinical Outcomes of Start-Low, Go-Slow Methadone Initiation for Cancer-Related Pain: What's the Hurry?
Hawley P; Chow L; Fyles G; Shokoohi A; O'Leary MJ; Mittelstadt M
J Palliat Med; 2017 Nov; 20(11):1244-1251. PubMed ID: 28595027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
